Clinical Trial Update: Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh [Phase 4]

View source ↗

Summary

This Phase 4 trial evaluated a short course of AmBisome (liposomal amphotericin B) for treating post-kala-azar dermal leishmaniasis (PKDL) in Bangladesh. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-kala-azar Dermal Leishmaniasis

Drugs mentioned

• AMBISOME (AMPHOTERICIN B)

Snippet

Sponsor: Medecins Sans Frontieres, Netherlands | Conditions: Post-kala-azar Dermal Leishmaniasis | Phase 4 | Status: COMPLETED